collected and calculated, along with prostate specific antigen (PSA), pathological stage, and pathological grade. Patients were included for analysis if all of the above values were available. Primary and secondary outcomes were biochemical recurrence (BCR) (defined as 2 consecutive PSA values of 0.2 ng/dL or greater) and time to BCR, respectively. Median follow-up was 2.75 years post- RARP. Student t-tests were used to compare means of preoperative and 3 month TT and FT for patients who experienced BCR vs. those who did not. Multivariate analyses was performed to assess for influ- ence of age, pathological grade, pathological stage, TT (pre-op and at 3 mos), and FT (pre-op and at 3 mos). RESULTS: Overall, 143/687 (20.8%) patients experienced BCR. Pre-operative FT (BCR: 5.42.31, no BCR: 6.183.48), 3 month FT (BCR: 6.082.74, no BCR: 7.143.83) and 3 month TT (BCR: 367179.78, no BCR: 402194.45) were significantly lower in BCR patients (p [ 0.004), (p [ 0.002), (p [ 0.048), respectively. After adjusting for age and pathological grade, a lower 3 month FT independently predicted time to BCR (p[0.038) along with pathologic stage (p[0.001 CONCLUSIONS: Low levels of FT may hasten time to BCR post-RARP. Men with low TT and FT may benefit from an oncologic standpoint with normalization of these values, possibly through testosterone replacement therapy. These results confirm that higher FT does not further the progression of prostate cancer. Source of Funding: None MP54-17 THE PREVALENCE, RISK FACTORS AND IMPACT ON QUALITY OF LIFE OF LYMPHEDEMA AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY WITH EXTENDED PELVIC LYMPH NODE DISSECTION. Yannic Raskin*, Cedric Jorissen, Steven Joniau, Wouter Everaerts, Leuven, Belgium INTRODUCTION AND OBJECTIVES: The therapeutic benefit of an extended pelvic lymph node dissection (ePLND) in the surgical treatment of localized prostate cancer is still open for debate. On the other hand, an ePLND is associated with significant additional peri- and postoperative complications, the most frequent one being secondary lymphedema. In this single center prospective analysis, we aim to determine the prevalence, possible risk factors and the effect on quality of life. METHODS: We have prospectively registered 139 patients who received a robot-assisted radical prostatectomy with ePLND from 2015 to 2018 at our center. Exclusion criteria were conversion to open procedure, salvage cases and follow-up <5mo. The presence of lymphedema was evaluated in a standardized manner. Quality of life was assessed for by the EORTC QLQ-C30. Four possible risk factors were analyzed: BMI, age, adjuvant radiotherapy and presence of a symptomatic lymphocele. RESULTS: After applying inclusion and exclusion criteria, the study population counted 139 patients. In 29/139 (20.8%) patients, lymphedema was present during the last consultation. Significant swelling existed in 16/29 (55.1%) patients in the upper left leg, in 15/29 (51.7%) in the upper right leg, in 14/29 (48.2%) in the lower left leg and in 17/29 (58.6%) in the lower right leg. Bilateral lymphedema occurred in 15/29 (51.7%) patients. Two patients (6.9%) presented with scrotal edema. Mean age was 64,7yo (SD  6.22) in the lymphedema group vs. 64,5yo (SD  6.75, p[0.974) in the non-lymphedema group. Mean pre-operative BMI was 27.4 kg/m2 (SD  3.61) vs. 26.25 kg/m2 (SD  2.96, p[0.161). Adjuvant radiotherapy was administered in 9/29 (31%) vs. 11/110 (10%, p[0.004). A symptomatic lymphocele formation had been present in 5/29 (17.2%) vs. 9/110 (8.2%, p[0.149). EORTC QLQ-C30 subgroups rated: global health status (80.39 vs 73.69), physical functioning (93.83 vs 85.88), role functioning (95.22 vs 77.54), emotional functioning (85.6 vs 76.62) and social functioning (92.67 vs 80.08). CONCLUSIONS: The prevalence of lymphedema after ePLND during radical prostatectomy (20.8 %) is much higher than previously reported. Lymphedema is associated with important effects on the physical and emotional well-being of patients. We confirm adjuvant radiotherapy as a risk factor for the development of lymphedema, whereas age, BMI and symptomatic lymphoceles were not withheld. Source of Funding: None MP54-18 IMPACT OF PELVIC LYMPH NODE YIELD DURING RADICAL PROSTATECTOMY ON LONG TERM CSS AND OS: A RETROSPECTIVE 5- AND 10-YEARS ANALYSIS ON A 1274 SERIES Maria Chiara Sighinolfi*, Modena, Italy; Ahmed Eissa, Tanta, Egypt; Marco Sandri, Brescia, Italy; Stefano Puliatti, Maria Giuseppa Vitale, Alessio Bruni, Modena, Italy; Alberto Romano, Capri, Italy; Luca Reggiani Bonetti, Ilaria Bagni, Modena, Italy; Giancarlo Peracchia, Capri, Italy; Riccardo Grisanti, Sassuolo, Italy; Ahmed Zoeir, Tanta, Egypt; Salvatore Micali, Modena, Italy; Vipul Patel, Orlando, FL; Giampaolo Bianchi, Bernardo Maria Rocco, Modena, Italy INTRODUCTION AND OBJECTIVES: Lymph node dissection (LND) during radical prostatectomy (RP) for prostate cancer (PCa) aims to provide information for staging and prognosis, while oncological and survival benefits are debatable. The potential harms of LND should be balanced with the benefits on an individual risk assessment. Given that the eligibility to an eLND is based on the prediction of an aggressive nodal disease, we aimed to explore the actual 5- and 10- years cancer specific survival (CSS) benefit of a LND with the removal of more than 11 nodes on patients with adverse pathological findings (APF) at RP. METHODS: From the Pathological Registry of Modena (Italy), data on ORP with LND performed since 2000 were retrospectively assessed. Patients with at least 5- and 10-years follow up were considered (1,274 and 581 patients, respectively). APF at RP were recorded as follows: pT3a in 27.9% and a GS  7 in 53.0%. Nodal invasion was evident in 6.4%(n[82), and positive surgical margins in 35.4% (n[451). The median node yield was similar among organ confined and locally advanced disease (p[0.798) and among GS[ 6 and GS 7(p[0.392). Consistent with previous Literature, we divided the number of nodes removed according to a cut-off point of 11 [10 versus 11 (More Extended[ME-LND)]: the correlation between 5- and 10-years CSS and a ME-LND is considered as the primary outcome. Since lit- tle is known about the effects of an extended procedure in a pN0 population, the impact of ME-LND on CSS of pN0 with APF at RP is the secondary endpoint. RESULTS: A ME-LND template was not related to 5- and 10- years CSS in the whole series and in the subgroup with nodal disease (p[ 0.33). Overall, considering pN0 PCa, a 5-years (SHR Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e791 Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.